Clinical Trial Update: A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC [Phase 3]

View source ↗

Summary

Phase 3 study evaluating apalutamide plus androgen deprivation therapy (ADT) versus ADT alone in men with metastatic hormone-sensitive prostate cancer; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-01-18